Authors: Decensi, A Torrisi, R Bruno, S Costantini, M Curotto, A Nicolo, G Malcangi, B Baglietto, L Bruttini, GP Gatteschi, B Rondanina, G Varaldo, M Perloff, M Malone, WF Bruzzi, P

Citation: A. Decensi et al., Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point, CANC EPID B, 9(10), 2000, pp. 1071-1078

Authors: Bruno, S Torrisi, R Costantini, M Baglietto, L Fontana, V Gatteschi, B Melioli, G Nicolo, G Curotto, A Malcangi, B Bruttini, GP Varaldo, M Bruzzi, P Decensi, A

Citation: S. Bruno et al., Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial, J CELL BIOC, 76(2), 2000, pp. 311-321

Authors: Barbui, P Casadei, G Ceccopieri, C Ciotola, R Comeri, G Cruciani, E de Joanna, F Ferrando, U Gritti, A Guarna, A Jacobellis, U Lai, S Leoni, S Maccanico, A Miano, L Milani, C Borin, R Nicolosi, D Pacifico, P Parma, A Rossetti, R Sacca, V Trocino, S Valentino, RV Varaldo, M

Citation: P. Barbui et al., Safety, efficacy and impact on patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH, EUR UROL, 37(6), 2000, pp. 680-686

Authors: Semino, C Pietra, G Semino, A Falco, M Varaldo, M Melioli, G

Citation: C. Semino et al., Normal epithelial cells modulating HLA class I surface molecules are susceptible to lysis mediated by CD3(+) and CD3(-) "nonspecific" killer cells, CELL IMMUN, 190(2), 1998, pp. 183-190